Justin Lambert/DigitalVision via Getty ImagesTopline Summary and Update iTeos Therapeutics (NASDAQ:ITOS) is an immunotherapy-focused biotech working on a molecule targeting TIGIT, an elusive checkpoint with a checkered past in cancer clinical research. In my last writeup of the company, I indicated growing optimism for the ITOS approach, particularly in lung cancer. I expected that we might see a data readout at this year's ESMO meeting. And here we are, ESMO 2024, and we have some more findings to chew ...